Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases

Masayuki Saruta, Konstantinos A. Papadakis

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including integrins and chemokine receptors, have been successfully targeted for the treatment of IBD. These agents have shown great promise for the induction and maintenance of remission for both Crohn disease and ulcerative colitis. This article discusses currently approved prototypic agents for the treatment of IBD (natalizumab, anti-α4 integrin; vedolizumab, anti-α4β7 integrin), and several other agents in the same class currently under development.

Original languageEnglish (US)
Pages (from-to)581-601
Number of pages21
JournalGastroenterology Clinics of North America
Volume43
Issue number3
DOIs
StatePublished - Sep 2014

Keywords

  • Chemokine receptors
  • Crohn disease
  • Etrolizumab
  • Inflammatory bowel disease
  • Integrins
  • Natalizumab
  • Ulcerative colitis
  • Vedolizumab

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases'. Together they form a unique fingerprint.

  • Cite this